IPO registrations (S-1, F-1) · Registrants
ArriVent BioPharma, Inc.
- SEC CIK
- 1868279 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2024-01-05, last 2024-01-23; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2024-01-26; declared effective 2024-01-25
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 18 CAMPUS BLVD., SUITE 100, Newtown Square, PA 19073-3269
- Ticker
- AVBP (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- ArriVent BioPharma, Inc. on the corporate pages
Offering terms
- Proposed price range
- $17.00–$19.00 per share (S-1/A filed 2024-01-23)
- Final price
- $18.00 per share, within the range (424B4 filed 2024-01-26, an initial public offering)
- Shares sold
- 9,722,222
- Gross proceeds
- $174,999,996 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol AVBP
- Lead underwriters
- Goldman Sachs; Jefferies; Citigroup
- Syndicate
- LifeSci Capital
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Arrivent Biopharma, Inc. Fuzzy (name and state)
- Business registration: Arrivent Biopharma, Inc. Fuzzy (name and state)
- Business registration: Arrivent Biopharma, Inc. Fuzzy (name and state)
- Business registration: Arrivent Biopharma, Inc. Fuzzy (name and state)
- Business registration: ArriVent BioPharma, Inc. Fuzzy (name and state)
- Business registration: ArriVent BioPharma, Inc. Fuzzy (name and state)
- Business registration: ArriVent BioPharma, Inc. Fuzzy (name and state)
- Business registration: ARRIVENT BIOPHARMA, INC. Fuzzy (name and state)
- Business registration: ARRIVENT BIOPHARMA, INC. Fuzzy (name and state)
- Business registration: ARRIVENT BIOPHARMA, INC. Fuzzy (name and state)
- Business registration: ARRIVENT BIOPHARMA, INC. Fuzzy (name and state)
- Business registration: ARRIVENT BIOPHARMA, INC. Fuzzy (name and state)
- Form D issuer: ArriVent Biopharma, Inc. EXACT (CIK (EXACT))
- SEC filer: ArriVent Biopharma, Inc. EXACT (CIK (EXACT))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2024-01-05 | S-1 | S-1 (registration) | ArriVent Biopharma, Inc. | 0001104659-24-001804 ↗ |
| 2024-01-22 | S-1/A | S-1/A (amendment) | ArriVent Biopharma, Inc. | 0001104659-24-005364 ↗ |
| 2024-01-23 | S-1/A | S-1/A (amendment) | ArriVent Biopharma, Inc. | 0001104659-24-005933 ↗ |
| 2024-01-25 | S-1MEF | S-1MEF (added securities) | ArriVent Biopharma, Inc. | 0001104659-24-006807 ↗ |
| 2024-01-25 | EFFECT | EFFECT (declared effective) | ArriVent Biopharma, Inc. | 9999999995-24-000212 ↗ |
| 2024-01-26 | 424B4 | 424B4 (final prospectus) | ArriVent Biopharma, Inc. | 0001104659-24-007261 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-23 | S-1/A | registration statement | $17.00–$19.00 | 8,333,333 | - | Nasdaq AVBP | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2024-01-26 | 424B4 | final prospectus | $18.00 | 9,722,222 | $174,999,996 | Nasdaq AVBP | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| GORDON CARL L | Director,TenPercentOwner | 2 | 2024 | ||
| HEALY JAMES | Director | 2 | 2024 | ||
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | TenPercentOwner | 3 | 2024–2026 | ||
| Jallal Bahija | Director | 2 | 2024 | ||
| Kastenmayer James Paul | Officer | General Counsel | 3 | 2024–2026 | |
| Kung Winston | Officer | Chief Financial Officer | 3 | 2024–2026 | |
| LaChapelle Robin | Officer | Chief Operating Officer | 5 | 2024–2026 | |
| Lutzker Stuart | Director,Officer | President of R&D | 3 | 2024–2026 | |
| Nolet Chris | Director | 4 | 2024–2026 | ||
| OrbiMed Advisors IV Ltd | Director,TenPercentOwner | 2 | 2024 | ||
| ORBIMED ADVISORS LLC | Director,TenPercentOwner | 2 | 2024 | ||
| OrbiMed Asia GP IV, L.P. | Director,TenPercentOwner | 2 | 2024 | ||
| OrbiMed Capital GP VIII LLC | Director,TenPercentOwner | 2 | 2024 | ||
| Yao Zhengbin | Director,Officer | President and CEO | 3 | 2024–2026 | |
| HHLR ADVISORS, LTD. | TenPercentOwner | 2 | 2024–2026 | ||
| Peterson Kristine | Director | 4 | 2024–2026 | ||
| Hohneker John | Director | 4 | 2024–2026 | ||
| Parsey Merdad | Director | 4 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2022-12-29 | ArriVent Biopharma, Inc. | Biotechnology | $145,000,000 | $109,999,989 | 17 | 1 |
| 2021-06-23 | ArriVent Biopharma, Inc. | Biotechnology | $150,000,000 | $150,000,000 | 10 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Arrivent Biopharma, Inc. | PA | State business registries | name and state |
| Business registration | Arrivent Biopharma, Inc. | PA | State business registries | name and state |
| Business registration | Arrivent Biopharma, Inc. | PA | State business registries | name and state |
| Business registration | Arrivent Biopharma, Inc. | PA | State business registries | name and state |
| Business registration | ArriVent BioPharma, Inc. | PA | State business registries | name and state |
| Business registration | ArriVent BioPharma, Inc. | PA | State business registries | name and state |
| Business registration | ArriVent BioPharma, Inc. | PA | State business registries | name and state |
| Business registration | ARRIVENT BIOPHARMA, INC. | PA | State business registries | name and state |
| Business registration | ARRIVENT BIOPHARMA, INC. | PA | State business registries | name and state |
| Business registration | ARRIVENT BIOPHARMA, INC. | PA | State business registries | name and state |
| Business registration | ARRIVENT BIOPHARMA, INC. | PA | State business registries | name and state |
| Business registration | ARRIVENT BIOPHARMA, INC. | PA | State business registries | name and state |
| Form D issuer | ArriVent Biopharma, Inc. | PA | Form D private offerings | CIK (EXACT) |
| Nonprofit | M NIGHT SHYAMALAN FOUNDATION INC | PA | Nonprofits (IRS Form 990) | same street address and ZIP code, 18 CAMPUS BLVD STE 100 19073 (FUZZY: a shared address, not proof of a shared organization) |
| SEC filer | ArriVent BioPharma, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | ArriVent BioPharma, Inc. | PA | Trademarks (USPTO) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, PA first:
- COLLAGENEX PHARMACEUTICALS INC PA
- ORAPHARMA INC PA
- VICURON PHARMACEUTICALS INC PA
- INOVIO PHARMACEUTICALS, INC. PA
- ADOLOR CORP PA
- PROTARGA INC PA
- Traws Pharma, Inc. PA
- MADRIGAL PHARMACEUTICALS, INC. PA
- Vitae Pharmaceuticals, Inc PA
- PhaseBio Pharmaceuticals Inc PA
In other datasets, the same topic (Health) in PA:
- Nonprofit: 445 FOUNDATION (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health